氨基糖苷类药物与新型β-内酰胺类药物对多重耐药铜绿假单胞菌的体外协同活性
In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.
作者信息
Giamarellou H, Zissis N P, Tagari G, Bouzos J
出版信息
Antimicrob Agents Chemother. 1984 Apr;25(4):534-6. doi: 10.1128/AAC.25.4.534.
Abstract
The in vitro interactions between amikacin, netilmicin, tobramycin, gentamicin, and various antipseudomonal beta-lactams were studied by the agar dilution checkerboard technique against 30 Pseudomonas aeruginosa strains resistant to all tested antibiotics. Amikacin produced more frequent synergy both at the total and clinically applicable level. Among the beta-lactams, clinically relevant synergistic interactions were obtained in the following order: ceftazidime and ceftriaxone greater than moxalactam greater than aztreonam greater than cefotaxime greater than azlocillin greater than cefoperazone greater than cefsulodin greater than carbenicillin.
摘要
采用琼脂稀释棋盘法，针对30株对所有受试抗生素均耐药的铜绿假单胞菌菌株，研究了阿米卡星、奈替米星、妥布霉素、庆大霉素与各种抗假单胞菌β-内酰胺类药物之间的体外相互作用。在总量及临床适用水平上，阿米卡星产生协同作用的频率更高。在β-内酰胺类药物中，临床相关的协同相互作用按以下顺序排列：头孢他啶和头孢曲松大于拉氧头孢大于氨曲南大于头孢噻肟大于阿洛西林大于头孢哌酮大于磺苄西林大于羧苄西林。
相似文献
1
In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.氨基糖苷类药物与新型β-内酰胺类药物对多重耐药铜绿假单胞菌的体外协同活性
Antimicrob Agents Chemother. 1984 Apr;25(4):534-6. doi: 10.1128/AAC.25.4.534.
2
Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.氨基糖苷类药物与β-内酰胺类药物联合用于抗革兰氏阴性菌。体外协同作用及化学相互作用的评估。
Am J Med. 1986 Jun 30;80(6B):126-37. doi: 10.1016/0002-9343(86)90490-0.
3
4
[Comparative bactericidal activity of beta-lactam-aminoglycoside combinations against Pseudomonas aeruginosa].β-内酰胺类抗生素与氨基糖苷类抗生素联合应用对铜绿假单胞菌的杀菌活性比较
Nouv Presse Med. 1982 Nov 18;11(46):3400-4.
5
[In vitro sensitivity at 18 antibiotics of 192 strains of Pseudomonas aeruginosa isolated at Garches Hospital].[加歇医院分离出的192株铜绿假单胞菌对18种抗生素的体外敏感性]
Pathol Biol (Paris). 1987 May;35(5):558-62.
6
Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant Pseudomonas aeruginosa strains.依诺沙星（CI-919，AT-2266）与十一种抗铜绿假单胞菌药物对氨基糖苷类敏感和耐药的铜绿假单胞菌菌株的体外活性比较
Antimicrob Agents Chemother. 1984 Sep;26(3):417-8. doi: 10.1128/AAC.26.3.417.
7
In-vitro susceptibility of Pseudomonas aeruginosa to old and new beta-lactam antibiotics and aminoglycosides.铜绿假单胞菌对新旧β-内酰胺类抗生素及氨基糖苷类抗生素的体外敏感性
J Antimicrob Chemother. 1983 Jun;11(6):511-5. doi: 10.1093/jac/11.6.511.
8
Comparison of the in vitro activity of new beta-lactams and aminoglycosides against clinical isolates of Pseudomonas aeruginosa.新型β-内酰胺类药物与氨基糖苷类药物对铜绿假单胞菌临床分离株的体外活性比较。
Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol. 1982 Oct;253(1):110-20.
9
Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.新型β-内酰胺类抗生素对囊性纤维化患者铜绿假单胞菌分离株的活性。
Antimicrob Agents Chemother. 1981 Oct;20(4):545-6. doi: 10.1128/AAC.20.4.545.
10
In-vitro activity of ciprofloxacin and other beta-lactam antibiotics against gentamicin- and carbenicillin-resistant isolates of Pseudomonas aeruginosa.环丙沙星及其他β-内酰胺类抗生素对庆大霉素和羧苄西林耐药的铜绿假单胞菌分离株的体外活性
J Chemother. 1991 Feb;3(1):3-5. doi: 10.1080/1120009x.1991.11739054.
引用本文的文献
1
Unlocking Enhanced Efficacy of Aminoglycoside Antibiotics Against Pseudomonas aeruginosa.解锁氨基糖苷类抗生素对铜绿假单胞菌的增强疗效。
Microb Biotechnol. 2025 Jun;18(6):e70174. doi: 10.1111/1751-7915.70174.
2
Pharmacological strategies for targeting biofilms in otorhinolaryngologic infections and overcoming antimicrobial resistance (Review).针对耳鼻咽喉科感染中的生物膜及克服抗菌药物耐药性的药理学策略（综述）
Biomed Rep. 2025 Apr 9;22(6):95. doi: 10.3892/br.2025.1973. eCollection 2025 Jun.
3
Critical role of growth medium for detecting drug interactions in Gram-negative bacteria that model responses.生长培养基在模拟反应的革兰氏阴性菌中检测药物相互作用的关键作用。
mBio. 2024 Mar 13;15(3):e0015924. doi: 10.1128/mbio.00159-24. Epub 2024 Feb 16.
4
Optimizing Antimicrobial Drug Dosing in Critically Ill Patients.优化重症患者的抗菌药物给药方案
Microorganisms. 2021 Jun 28;9(7):1401. doi: 10.3390/microorganisms9071401.
5
Antibiotic prescribing practices in paediatric septic shock in a tertiary care hospital in a resource limited setting: an audit.资源有限环境下三级医疗保健医院儿科感染性休克的抗生素使用情况：一项审计。
Pan Afr Med J. 2019 Nov 7;34:133. doi: 10.11604/pamj.2019.34.133.15820. eCollection 2019.
6
Species-specific activity of antibacterial drug combinations.抗菌药物组合的种属特异性活性。
Nature. 2018 Jul;559(7713):259-263. doi: 10.1038/s41586-018-0278-9. Epub 2018 Jul 4.
7
Biophysical and enzymatic properties of aminoglycoside adenylyltransferase AadA6 from .来自……的氨基糖苷腺苷酸转移酶AadA6的生物物理和酶学性质
Biochem Biophys Rep. 2015 Sep 18;4:152-157. doi: 10.1016/j.bbrep.2015.09.011. eCollection 2015 Dec.
8
Evaluation of the Interaction between the Poincianella pyramidalis (Tul.) LP Queiroz Extract and Antimicrobials Using Biological and Analytical Models.使用生物学和分析模型评估绒毛猴耳环（Poincianella pyramidalis (Tul.) LP Queiroz）提取物与抗菌剂之间的相互作用。
PLoS One. 2016 May 18;11(5):e0155532. doi: 10.1371/journal.pone.0155532. eCollection 2016.
9
Pairwise antibiotic interactions in Escherichia coli: triclosan, rifampicin and aztreonam with nine other classes of antibiotics.大肠杆菌中的抗生素两两相互作用：三氯生、利福平、氨曲南与其他九类抗生素的相互作用
J Antibiot (Tokyo). 2016 Nov;69(11):791-797. doi: 10.1038/ja.2016.26. Epub 2016 Mar 9.
10
Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections.广泛耐药铜绿假单胞菌感染成年癌症患者的特征、风险因素和结局。
Infection. 2014 Aug;42(4):721-8. doi: 10.1007/s15010-014-0635-z. Epub 2014 Jun 10.
本文引用的文献
1
Prediction and significance of synergy between antibiotics used for treatment for gram-negative sepsis.用于治疗革兰氏阴性菌败血症的抗生素之间协同作用的预测及意义
Infection. 1980;Suppl 1:45-8. doi: 10.1007/BF01644935.
2
Clinical efficacy of aminoglycosides: an example of balance between microbiology and pharmacology.氨基糖苷类药物的临床疗效：微生物学与药理学平衡的一个实例
J Antimicrob Chemother. 1981 Jul;8 Suppl A:143-9. doi: 10.1093/jac/8.suppl_a.143.
3
Antibiotics of choice in suspected serious sepsis.疑似严重脓毒症时的首选抗生素。
J Antimicrob Chemother. 1981 Jul;8 Suppl A:133-42. doi: 10.1093/jac/8.suppl_a.133.
4
Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporins.阿米卡星联合用药对中度敏感于第三代头孢菌素的肠杆菌科细菌的抗菌活性。
Antimicrob Agents Chemother. 1982 Dec;22(6):985-9. doi: 10.1128/AAC.22.6.985.
5
Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens.新型β-内酰胺类抗菌剂与阿米卡星对铜绿假单胞菌和粘质沙雷氏菌的体外协同活性比较
Antimicrob Agents Chemother. 1981 Aug;20(2):239-43. doi: 10.1128/AAC.20.2.239.
6
Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.头孢哌酮、头孢噻肟、拉氧头孢和羧苄西林与妥布霉素联合应用对铜绿假单胞菌的比较协同活性。
Antimicrob Agents Chemother. 1981 Feb;19(2):332-4. doi: 10.1128/AAC.19.2.332.
7
Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.羟羧氧酰胺菌素单独及与庆大霉素联合对铜绿假单胞菌的杀菌及协同活性。
Antimicrob Agents Chemother. 1983 Jan;23(1):179-81. doi: 10.1128/AAC.23.1.179.
8
Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.在使用羟羧氧酰胺菌素治疗铜绿假单胞菌感染期间，对β-内酰胺类和氨基糖苷类抗生素产生耐药性。
Antimicrob Agents Chemother. 1982 Dec;22(6):1037-41. doi: 10.1128/AAC.22.6.1037.
9
Mechanisms of resistance to aminoglycosides.对氨基糖苷类抗生素的耐药机制。
Am J Med. 1977 Jun;62(6):868-72. doi: 10.1016/0002-9343(77)90654-4.
10
Pseudomonas bacteremia. Review of 108 cases.假单胞菌血症。108例病例回顾。
Am J Med. 1976 Apr;60(4):501-8. doi: 10.1016/0002-9343(76)90716-6.
Zotero 插件